Emily Van Meter
Overview
Explore the profile of Emily Van Meter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saeed H, Yalamanchi S, Liu M, Van Meter E, Gul Z, Monohan G, et al.
Hematol Oncol Stem Cell Ther
. 2018 Feb;
11(2):90-95.
PMID: 29398592
Objectives: Allogeneic hematopoietic stem cell transplant (HCT) continues to evolve with the treatment in higher risk patient population. This practice mandates stringent update and validation of risk stratification prior to...
2.
Dignan M, White C, Schoenberg N, Shelton B, Feltner F, Slone S, et al.
Health Behav Policy Rev
. 2017 Aug;
1(1):6-15.
PMID: 28761895
Objective: In collaboration with rural county health departments (CHDs), we developed a patient navigation intervention to increase adherence to follow-up recommendations for women with abnormal Pap tests. Methods: Local women...
3.
4.
Ely G, White C, Jones K, Feltner F, Gomez M, Shelton B, et al.
Soc Work Health Care
. 2014 Feb;
53(2):83-95.
PMID: 24483330
This article describes a community-based Patient Navigation (PN) project conducted to identify potential barriers to seeking follow-up cervical cancer care in southeastern Kentucky. Patient navigators (PNs) were placed in cervical...
5.
Massarweh S, Romond E, Black E, Van Meter E, Shelton B, Kadamyan-Melkumian V, et al.
Breast Cancer Res Treat
. 2013 Dec;
143(2):325-32.
PMID: 24327334
Fulvestrant, which degrades ER, is used after AI failure in metastatic breast cancer but resistance develops quickly. We hypothesized that using everolimus to inhibit mTOR, a key signaling pathway in...
6.
Dignan M, Shelton B, Slone S, Tolle C, Mohammad S, Schoenberg N, et al.
Prev Med
. 2013 Nov;
58:70-4.
PMID: 24212061
Objective: This report describes findings from a randomized controlled trial of an intervention to increase colorectal cancer (CRC) screening in primary care practices in Appalachian Kentucky. Methods: Sixty-six primary care...
7.
Narayanasamy G, Smith A, Van Meter E, McGarry R, Molloy J
Med Phys
. 2013 Sep;
40(9):091714.
PMID: 24007147
Purpose: To assess the hypothesis that the volume of whole brain that receives a certain dose level is primarily dependent on the treated volume rather than on the number, shape,...
8.
Slone S, White C, Shelton B, Van Meter E, DeSimone C, Schoenberg N, et al.
J Womens Health (Larchmt)
. 2012 Nov;
22(2):147-52.
PMID: 23145889
Purpose: Adherence with recommended follow-up after an abnormal Pap test is a critical step in the prevention of cervical cancer. Here, we focused on identifying inconsistencies between self-reported and health...
9.
Hudspeth M, Hill T, Lewis J, Van Meter E, Ragucci D
Pediatr Blood Cancer
. 2010 Feb;
54(7):970-5.
PMID: 20135703
Background: A survey of National Marrow Donor Program transplant centers in 1995 demonstrated a wide range of immunization practices in post-hematopoietic stem cell transplant (HSCT) recipients, which led to the...